Recombinant Porphobilinogen deaminase (hemC)

What is porphobilinogen deaminase and what is its role in heme biosynthesis?

Porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane synthase (HMBS) or pre-uroporphyrinogen synthase (UPS), functions as the third enzyme in the heme biosynthetic pathway. It catalyzes the head-to-tail condensation of four porphobilinogen (PBG) molecules to form the linear hydroxymethylbilane . This reaction is critical for the subsequent synthesis of heme, which is essential for all of the body's organs, although it is most abundant in the blood, bone marrow, and liver. Heme serves as an essential component of iron-containing proteins called hemoproteins, including hemoglobin .

The enzyme contains a dipyrromethane cofactor at the active site that plays a crucial role in the catalytic mechanism. When the substrate porphobilinogen binds to this cofactor, it forms three intermediate complexes designated as ES, ES2, and ES3 .

What are the physical properties of recombinant porphobilinogen deaminase?

Recombinant porphobilinogen deaminase from E. coli has been extensively characterized with the following properties:

Human recombinant HMBS has slightly different properties:

What methods are used to measure porphobilinogen deaminase activity?

A common method for measuring PBGD activity involves the spectrophotometric determination of uroporphyrin, which is formed by the light-induced oxidation of uroporphyrinogen (the immediate product of enzymatic deamination).

A modified protocol from Ickowicz Schwartz et al. involves:

• Incubating the cell extract (2 mg of proteins) at 37°C for 30 min in the dark with 1 ml of 1 mM porphobilinogen and 250 mM sodium phosphate-citric acid buffer (pH 7.5)

• Adding 2 ml of ethyl acetate-acetic acid (3:1, vol/vol)

• Separating the reaction mixture by centrifugation at 1,000 × g

• Exposing to ambient light at room temperature for 15 min

• Taking 1.6 ml of the upper layer containing porphyrin and mixing with 1 ml of 0.5 M HCl

• Separating the mixture by centrifugation at 2,500 × g for 10 min

• Analyzing the lower layer using a fluorescence microplate reader at excitation and emission filter settings of 409 and 595 nm, respectively

What expression systems are recommended for producing recombinant porphobilinogen deaminase?

Escherichia coli has proven to be an efficient expression system for producing recombinant porphobilinogen deaminase. Successful expression has been achieved using an overproducing recombinant strain of E. coli harboring a hemC-containing plasmid, which has permitted the purification of milligram quantities of the enzyme .

For human HMBS, mammalian expression systems have been successfully employed. Commercial recombinant human HMBS is produced in human cells, expressing the target gene encoding Ser2-His361 with a 6His tag at the C-terminus . This approach may help ensure proper folding and post-translational modifications that are important for full activity.

In fungal systems such as Aspergillus nidulans, the hemC gene has been shown to be essential for growth under normal conditions. Researchers have developed conditional mutants by replacing the chromosomal hemC gene promoter with the alcA gene promoter, which is induced by ethanol or threonine and repressed by glucose . This approach allows for controlled expression and study of the enzyme's function.

What purification techniques yield high-quality recombinant porphobilinogen deaminase?

The purification protocol for recombinant porphobilinogen deaminase typically involves multiple chromatographic steps. While the specific details of the purification protocol are not fully described in the provided search results, recombinant human HMBS with a C-terminal 6His tag can be purified using immobilized metal affinity chromatography (IMAC) .

For the final product, purity should exceed 95% as determined by reducing SDS-PAGE . The purified enzyme preparation should be assessed for endotoxin levels, which should be maintained below 1.0 EU per μg as determined by the LAL method .

What are the optimal storage conditions for maintaining recombinant porphobilinogen deaminase activity?

Recombinant human HMBS is typically provided as a lyophilized powder from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4 . For storage:

• Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C

• Reconstituted protein solutions can be stored at 4-8°C for 2-7 days

• Aliquots of reconstituted samples remain stable at < -20°C for 3 months

When shipping, the lyophilized product should be transported with ice packs to maintain stability .

How has recombinant porphobilinogen deaminase been utilized in therapeutic research?

Recombinant human porphobilinogen deaminase (rhPBGD) has been investigated as a potential therapeutic for acute intermittent porphyria (AIP), a rare disease caused by a genetic mutation affecting the hepatic activity of porphobilinogen deaminase. Researchers have developed novel therapies based on the administration of different formulations of rhPBGD linked to the ApoAI lipoprotein .

The fusion protein of rhPBGD with ApoAI circulates in the blood, incorporating into HDL and penetrating hepatocytes. This approach represents a potential alternative to hemin for the treatment of AIP .

A mechanistic model has been developed to characterize the enzymatic restoration effects of this novel therapy. Various formulations of rhPBGD linked to ApoAI were administered to AIP mice in which a porphyric attack was triggered by intraperitoneal phenobarbital. Treatment with rhPBGD formulations restored PBGD activity, increasing up to 51 times the value of the rate of total porphyrin formation estimated from baseline .

What methodological approaches can be used to study enzyme kinetics of recombinant porphobilinogen deaminase?

Studies of enzyme kinetics for recombinant porphobilinogen deaminase have revealed insights into its catalytic mechanism. The enzyme has a Km of 19 ± 7 μM for its substrate porphobilinogen . The substrate binds to the active-site dipyrromethane cofactor to form three intermediate complexes: ES, ES2, and ES3 .

For kinetic studies, researchers can employ spectrophotometric assays as described in section 1.3, or can develop more complex mechanistic modeling approaches. For example, non-linear mixed-effects analysis has been used to analyze data from therapeutic studies, characterizing the amounts of heme precursors excreted in urine over time for different formulations of rhPBGD .

A mechanistic model can unravel several mechanisms in the heme pathway, such as the regulation of 5-aminolevulinic acid (ALA) synthesis by heme. Parameters that can be determined include:

• Maximum rate of PBG conversion (Vmax)

• Parameter that regulates the magnitude of heme inhibition on hepatic ALA synthesis (γHeme)

• Parameter modulating the effect of excess PBG on the transit between hepatic ALA and hepatic PBG (γPBGD)

What molecular biology techniques are useful for studying hemC gene function?

Several molecular biology techniques have proven valuable for studying the hemC gene function:

• Gene Disruption: To construct a hemC disruption cassette, researchers have amplified the 5′ untranslated region of hemC by PCR, digested it with appropriate restriction enzymes, and inserted it into a plasmid containing a selectable marker. A similar approach is used for the 3′ region of hemC. The resulting construct is then used to transform the target organism .

• Conditional Mutants: For essential genes like hemC, conditional mutants can be generated by replacing the native promoter with a regulatable promoter. For example, in A. nidulans, the chromosomal gene promoter for hemC has been replaced with the alcA gene promoter, which is induced by ethanol or threonine and repressed by glucose .

• Southern Blot Analysis: This technique has been used to confirm gene disruption or promoter replacement. DNA probes are amplified with specific primer sets, labeled using a digoxigenin (DIG) PCR labeling kit, and used for hybridization. Signals can be detected using a luminescent image analyzer .

How do defects in HMBS lead to acute intermittent porphyria?

Acute intermittent porphyria (AIP) is a rare disease caused by a genetic mutation affecting the hepatic activity of porphobilinogen deaminase . As PBGD is the third enzyme in the heme biosynthetic pathway, defects in this enzyme lead to accumulation of heme precursors, particularly 5-aminolevulinic acid (ALA) and porphobilinogen (PBG) .

The accumulation of these precursors is associated with the clinical manifestations of AIP, which can include acute attacks characterized by abdominal pain, neurological symptoms, and psychiatric disturbances. These attacks can be triggered by various factors, including certain medications like phenobarbital .

What are the latest approaches for enzyme replacement therapy in HMBS deficiency?

Recent research has focused on the development of enzyme replacement therapy using recombinant human PBGD (rhPBGD) linked to the ApoAI lipoprotein . This fusion protein circulates in the blood, incorporating into HDL and penetrating hepatocytes, which are the primary site of heme synthesis and the cells most affected in AIP.

In experimental models:

• Single intravenous doses of different formulations of rhPBGD linked to ApoAI were administered to AIP mice

• Porphyric attacks were triggered by intraperitoneal phenobarbital

• Treatment restored PBGD activity, increasing up to 51 times the value of the rate of total porphyrin formation

• Model-based simulations showed that several formulation prototypes provided efficient protective effects when administered up to 1 week prior to the occurrence of the AIP attack

This approach represents a potential alternative to hemin, which is the current standard treatment for acute attacks of AIP .

What experimental models are available for studying HMBS deficiency disorders?

The search results mention AIP mice as an experimental model for studying HMBS deficiency and testing potential therapeutic approaches . In these mice, a porphyric attack can be triggered by intraperitoneal administration of phenobarbital, which increases the demand for heme synthesis and thus exacerbates the enzymatic deficiency.

Data collected from these models typically include 24-hour urine excreted amounts of heme precursors:

• 5-aminolevulinic acid (ALA)

• Porphobilinogen (PBG)

• Total porphyrins (tPOR)

These parameters can be analyzed using non-linear mixed-effects analysis to develop mechanistic models of the heme biosynthetic pathway and to evaluate the effects of potential therapeutic interventions .

What are the challenges in optimizing recombinant HMBS for therapeutic use?

While recombinant human PBGD linked to ApoAI has shown promise in experimental models of AIP, several challenges remain in optimizing this approach for therapeutic use. These include:

• Formulation development to maximize stability and activity

• Optimizing delivery to hepatocytes

• Determining the optimal dosing regimen

• Assessing long-term safety and efficacy

• Evaluating potential immunogenicity of the recombinant protein

Model-based simulations have shown that several formulation prototypes provided efficient protective effects when administered up to 1 week prior to the occurrence of an AIP attack, suggesting that prophylactic administration may be a viable strategy .

How might comparative studies of different species' HMBS contribute to understanding enzyme function?

Comparative studies of HMBS from different species can provide valuable insights into the structure-function relationships of this enzyme. The search results mention that the gene-derived primary structure of the E. coli deaminase has been compared with that derived from the cDNA of the human enzyme .

The amino acid sequence of HMBS from Aspergillus nidulans (encoded by AN0121.3) shows similarity to those of the porphobilinogen deaminases of Saccharomyces cerevisiae (Hem3p, 44% identity) and E. coli (HemC, 35% identity) . These comparisons can help identify conserved regions that may be critical for enzyme function, as well as variable regions that might explain species-specific differences in catalytic activity or stability.

Such comparative studies could inform protein engineering efforts aimed at enhancing the properties of recombinant HMBS for therapeutic applications or for use as a research tool.